Guided Therapeutics (GTHP) Total Current Liabilities (2010 - 2025)

Guided Therapeutics has disclosed Total Current Liabilities across 16 years of filings, most recently posting $6.6 million for Q4 2025.

• Total Current Liabilities for Q4 2025 came in at $6.6 million, up 7.81% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.6 million (up 7.81% YoY), and the FY2025 annual result was $6.6 million, up 7.81% from the prior year.
• Total Current Liabilities came in at $6.6 million for Q4 2025 at Guided Therapeutics, up from $6.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $9.2 million in Q1 2021 to a low of $4.0 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $5.7 million (2021), against an average of $5.7 million.
• Across the five-year window, Total Current Liabilities tumbled 40.96% in 2022 and surged 33.45% in 2024, its largest moves.
• Guided Therapeutics' Total Current Liabilities stood at $5.7 million in 2021, then declined by 14.49% to $4.9 million in 2022, then retreated by 1.23% to $4.8 million in 2023, then grew by 27.99% to $6.2 million in 2024, then increased by 7.81% to $6.6 million in 2025.
• The last three Total Current Liabilities figures came in at $6.6 million (Q4 2025), $6.5 million (Q3 2025), and $6.4 million (Q2 2025), per Business Quant data.